Last updated: 11/08/2022 10:19:04
Phase 1 dose escalating study to assess safety, tolerability, Food effect and PK of CHR-5154 in Healthy Male Volunteers
Clinicaltrials.gov ID
EudraCT ID
EU CT Number
Not applicable
Trial status
Terminated (halted prematurely)
Terminated (halted prematurely)
Trial overview
Official title: A Phase 1 double-blind, randomised, placebo-controlled, dose escalating study to assess the safety and tolerability of single and multiple oral doses of CHR-5154 and the effect of the fasted and fed state on pharmacokinetics of CHR-5154 and CHR-5426 in healthy male volunteers
Trial description: Primary Objective:• To determine the safety and tolerability of single and multiple ascending oral doses of CHR-5154 in healthy volunteers.Secondary Objectives:• To determine the pharmacokinetic profile of CHR-5154 and its metabolite CHR-5426.• To compare the pharmacokinetic profile of CHR-5154 and CHR-5426 after a single dose of CHR-5154 in the fed and fasted state.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:
Number of volunteers with adverse events
Timeframe: Up to 10 days in Single ascending dose phase and 16 days in the Multiple ascending dose phase
Secondary outcomes:
To determine the pharmacokinetic profile of CHR-5154 and its metabolite CHR-5426.
Timeframe: Up to 48 hrs post dose
To compare the pharmacokinetic profile of CHR-5154 and CHR-5426 after a single dose of CHR-5154 in the fed and fasted state.
Timeframe: Up to 48 hours
Interventions:
Drug: CHR-5154
Drug: Placebo
Enrollment:
64
Observational study model:
Not applicable
Primary completion date:
2014-28-05
Time perspective:
Not applicable
Clinical publications:
Rebecca C. Furze, Judit Molnar, Nigel J. Parr, Faiz Ahmad, Yvette Henry, David Howe, Rajendra Singh, Martin Toal, Anna K. Bassil, Sharon G. Bernard, Robert P. Davis, Adele Gibson, N. Claire Maller, Catriona Sharp, David F. Tough, Rab K. Prinjha and Huw D. Lewis. Phase 1 and pre-clinical profiling of ESM-HDAC391, a myeloid-targeted histone deacetylase inhibitor, shows enhanced pharmacology and monocytopaenia. Br J Clin Pharmacol. 2022;
DOI: 10.1111/bcp.15428
PMID: 35655123
Medical condition
Arthritis, Rheumatoid
Product
GSK3117391, GSK3339189
Collaborators
Not applicable
Study date(s)
August 2013 to May 2014
Type
Interventional
Phase
1
Participation criteria
Sex
Male
Age
18 - 45 years
Accepts healthy volunteers
Yes
- 1. Healthy male volunteers aged 18-45.
- 2. Non-smokers from at least three months before receiving the first
- 1. Volunteers with history or presence of significant cardiovascular
- disease, pulmonary, hepatic, gallbladder or biliary tract, renal,
Inclusion and exclusion criteria
Inclusion criteria:
- 1. Healthy male volunteers aged 18-45. 2. Non-smokers from at least three months before receiving the first dose of study drug and for the duration of the study. 3. Body mass index (BMI) ≥ 18 and ≤ 32 kg/m2. 4. Body weight ≥ 50 kg and ≤ 120 kg at screening. 5. Able to voluntarily provide written informed consent to participate in the study. 6. Must understand the purposes and risks of the study and agree to follow the restrictions and schedule of procedures as defined in the protocol, as confirmed during the informed consent process. 7. Sexually active male volunteers must use two highly effective methods of contraception with their partners throughout the study and for 90 days after completion of the study. 8. Male volunteers must not donate sperm during the study and for 90 days after completion of the study. 9. Must be willing to consent to have data entered into The Over Volunteering Prevention System (TOPS). 10. The volunteer's primary care physician must confirm that there is nothing in their medical history that would preclude their enrolment into this clinical study
Exclusion criteria:
- 1. Volunteers with history or presence of significant cardiovascular disease, pulmonary, hepatic, gallbladder or biliary tract, renal, haematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, psychiatric disease or current infection. 2. Laboratory values at screening or baseline which are deemed to be clinically significant. 3. QTcF greater than 450 msec at screening. 4. Positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C. 5. Current or history of drug or alcohol abuse or a positive drugs of abuse or alcohol test at screening or check-in. 6. Participation in a clinical drug study during the 90 days preceding the initial dose in this study. 7. Any clinically significant illness within 30 days prior to study drug administration. 8. Donation of blood or blood products within 90 days prior to study drug administration, or at any time during the study, except as required by this protocol. 9. Volunteers who have a history or presence of any significant drug allergy. 10. Use of any prescription or over-the-counter medication (including vitamins, herbal and mineral supplements) within 30 days prior to study drug administration until the end of the study, with the exception of occasional paracetamol approved by the Investigator. 11. Strenuous exercise, as judged by the Investigator, within 72 hours prior to screening, within 72 hours prior to study drug administration and for the duration of the study until after the post-study medical. 12. Weekly alcohol intake exceeding the equivalent of 21 units per week. 13. Consumption of alcoholic beverages within 24 hours prior to study drug administration and during study confinement. 14. Consumption of caffeine or xanthine-containing products within 24 hours prior to confinement and during study confinement. 15. Consumption of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade or other products containing grapefruit or Seville oranges within 7 days prior to confinement and during study confinement. 16. Volunteers who, in the opinion of the Investigator, are unsuitable for participation in the study.
Trial location(s)
Study documents
Protocol
Available language(s): English
Statistical analysis plan
Available language(s): English
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Terminated (halted prematurely)
Actual primary completion date
2014-28-05
Actual study completion date
2014-28-05
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Results for study 201302 can be found on the GSK Clinical Study Register.
Click hereAccess to clinical trial data by researchers
Visit website